Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2018-10, Vol.29, p.viii725 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | viii725 |
| container_title | Annals of oncology |
| container_volume | 29 |
| creator | Rosenberg, J.E. Sharma, P. de Braud, F.G.M. Basso, U. Calvo, E. Bono, P. Morse, M. Ascierto, P.A. Lopez-Martin, J.A. Brossart, P. Rohrberg, K.S. Reguart, N. Lin, W.H. Meadows-Shropshire, S. Saci, A. Callahan, M. Siefker-Radtke, A.O. |
| description | |
| doi_str_mv | 10.1093/annonc/mdy424.038 |
| format | Article |
| fullrecord | <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdy424_038</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1093_annonc_mdy424_038</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1338-21ce93fc6802f821d85a1e815ca1035912605aceef257a3d2916fc04204459593</originalsourceid><addsrcrecordid>eNpNkctOwzAQRbMAifL4AHazbARp_UjSeIkiHpVK2dB15DpOaxrbke0C_Vj-hVSpEKuR7hzNXOlE0S1GE4wYnXJjrBFTXR9Skk4QLc6iEWKEJrOMphfRpfcfCKGcETaKfpbq07Z7zdcwXsbAW2skWAfKgLB6rQwPyhr4UmELqlOt0gM7j49I12-lCR7GXfDxQHVtH5q9Tjong5M8yBq0DNyHPhewdzZsZat4C4I7oYzVHMZ6Vcb3_UXR7mtlNtAjYP6aYdCb6W4Dd_8r0FMovztu_LFk46yGcivF7rX_CoiS6-i84a2XN6d5Fa2eHt_Ll2Tx9jwvHxaJwJQWCcFCMtqIvECkKQiui4xjWeBMcIxoxjDJUcaFlA3JZpzWhOG8ESglKE0zljF6FeHhrnDWeyebqnNKc3eoMKqOTqrBSTU4qXon9BfBVIZq</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Rosenberg, J.E. ; Sharma, P. ; de Braud, F.G.M. ; Basso, U. ; Calvo, E. ; Bono, P. ; Morse, M. ; Ascierto, P.A. ; Lopez-Martin, J.A. ; Brossart, P. ; Rohrberg, K.S. ; Reguart, N. ; Lin, W.H. ; Meadows-Shropshire, S. ; Saci, A. ; Callahan, M. ; Siefker-Radtke, A.O.</creator><creatorcontrib>Rosenberg, J.E. ; Sharma, P. ; de Braud, F.G.M. ; Basso, U. ; Calvo, E. ; Bono, P. ; Morse, M. ; Ascierto, P.A. ; Lopez-Martin, J.A. ; Brossart, P. ; Rohrberg, K.S. ; Reguart, N. ; Lin, W.H. ; Meadows-Shropshire, S. ; Saci, A. ; Callahan, M. ; Siefker-Radtke, A.O.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>DOI: 10.1093/annonc/mdy424.038</identifier><language>eng</language><ispartof>Annals of oncology, 2018-10, Vol.29, p.viii725</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1338-21ce93fc6802f821d85a1e815ca1035912605aceef257a3d2916fc04204459593</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Rosenberg, J.E.</creatorcontrib><creatorcontrib>Sharma, P.</creatorcontrib><creatorcontrib>de Braud, F.G.M.</creatorcontrib><creatorcontrib>Basso, U.</creatorcontrib><creatorcontrib>Calvo, E.</creatorcontrib><creatorcontrib>Bono, P.</creatorcontrib><creatorcontrib>Morse, M.</creatorcontrib><creatorcontrib>Ascierto, P.A.</creatorcontrib><creatorcontrib>Lopez-Martin, J.A.</creatorcontrib><creatorcontrib>Brossart, P.</creatorcontrib><creatorcontrib>Rohrberg, K.S.</creatorcontrib><creatorcontrib>Reguart, N.</creatorcontrib><creatorcontrib>Lin, W.H.</creatorcontrib><creatorcontrib>Meadows-Shropshire, S.</creatorcontrib><creatorcontrib>Saci, A.</creatorcontrib><creatorcontrib>Callahan, M.</creatorcontrib><creatorcontrib>Siefker-Radtke, A.O.</creatorcontrib><title>Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032</title><title>Annals of oncology</title><issn>0923-7534</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpNkctOwzAQRbMAifL4AHazbARp_UjSeIkiHpVK2dB15DpOaxrbke0C_Vj-hVSpEKuR7hzNXOlE0S1GE4wYnXJjrBFTXR9Skk4QLc6iEWKEJrOMphfRpfcfCKGcETaKfpbq07Z7zdcwXsbAW2skWAfKgLB6rQwPyhr4UmELqlOt0gM7j49I12-lCR7GXfDxQHVtH5q9Tjong5M8yBq0DNyHPhewdzZsZat4C4I7oYzVHMZ6Vcb3_UXR7mtlNtAjYP6aYdCb6W4Dd_8r0FMovztu_LFk46yGcivF7rX_CoiS6-i84a2XN6d5Fa2eHt_Ll2Tx9jwvHxaJwJQWCcFCMtqIvECkKQiui4xjWeBMcIxoxjDJUcaFlA3JZpzWhOG8ESglKE0zljF6FeHhrnDWeyebqnNKc3eoMKqOTqrBSTU4qXon9BfBVIZq</recordid><startdate>201810</startdate><enddate>201810</enddate><creator>Rosenberg, J.E.</creator><creator>Sharma, P.</creator><creator>de Braud, F.G.M.</creator><creator>Basso, U.</creator><creator>Calvo, E.</creator><creator>Bono, P.</creator><creator>Morse, M.</creator><creator>Ascierto, P.A.</creator><creator>Lopez-Martin, J.A.</creator><creator>Brossart, P.</creator><creator>Rohrberg, K.S.</creator><creator>Reguart, N.</creator><creator>Lin, W.H.</creator><creator>Meadows-Shropshire, S.</creator><creator>Saci, A.</creator><creator>Callahan, M.</creator><creator>Siefker-Radtke, A.O.</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201810</creationdate><title>Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032</title><author>Rosenberg, J.E. ; Sharma, P. ; de Braud, F.G.M. ; Basso, U. ; Calvo, E. ; Bono, P. ; Morse, M. ; Ascierto, P.A. ; Lopez-Martin, J.A. ; Brossart, P. ; Rohrberg, K.S. ; Reguart, N. ; Lin, W.H. ; Meadows-Shropshire, S. ; Saci, A. ; Callahan, M. ; Siefker-Radtke, A.O.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1338-21ce93fc6802f821d85a1e815ca1035912605aceef257a3d2916fc04204459593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rosenberg, J.E.</creatorcontrib><creatorcontrib>Sharma, P.</creatorcontrib><creatorcontrib>de Braud, F.G.M.</creatorcontrib><creatorcontrib>Basso, U.</creatorcontrib><creatorcontrib>Calvo, E.</creatorcontrib><creatorcontrib>Bono, P.</creatorcontrib><creatorcontrib>Morse, M.</creatorcontrib><creatorcontrib>Ascierto, P.A.</creatorcontrib><creatorcontrib>Lopez-Martin, J.A.</creatorcontrib><creatorcontrib>Brossart, P.</creatorcontrib><creatorcontrib>Rohrberg, K.S.</creatorcontrib><creatorcontrib>Reguart, N.</creatorcontrib><creatorcontrib>Lin, W.H.</creatorcontrib><creatorcontrib>Meadows-Shropshire, S.</creatorcontrib><creatorcontrib>Saci, A.</creatorcontrib><creatorcontrib>Callahan, M.</creatorcontrib><creatorcontrib>Siefker-Radtke, A.O.</creatorcontrib><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rosenberg, J.E.</au><au>Sharma, P.</au><au>de Braud, F.G.M.</au><au>Basso, U.</au><au>Calvo, E.</au><au>Bono, P.</au><au>Morse, M.</au><au>Ascierto, P.A.</au><au>Lopez-Martin, J.A.</au><au>Brossart, P.</au><au>Rohrberg, K.S.</au><au>Reguart, N.</au><au>Lin, W.H.</au><au>Meadows-Shropshire, S.</au><au>Saci, A.</au><au>Callahan, M.</au><au>Siefker-Radtke, A.O.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032</atitle><jtitle>Annals of oncology</jtitle><date>2018-10</date><risdate>2018</risdate><volume>29</volume><spage>viii725</spage><pages>viii725-</pages><issn>0923-7534</issn><doi>10.1093/annonc/mdy424.038</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2018-10, Vol.29, p.viii725 |
| issn | 0923-7534 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdy424_038 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| title | Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T06%3A52%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nivolumab%20(N)%20alone%20or%20in%20combination%20with%20ipilimumab%20(I)%20in%20patients%20(pts)%20with%20platinum-pretreated%20metastatic%20urothelial%20carcinoma%20(mUC),%20including%20the%20nivolumab%201%20mg/kg%20+%20ipilimumab%203%20mg/kg%20expansion%20from%20CheckMate%20032&rft.jtitle=Annals%20of%20oncology&rft.au=Rosenberg,%20J.E.&rft.date=2018-10&rft.volume=29&rft.spage=viii725&rft.pages=viii725-&rft.issn=0923-7534&rft_id=info:doi/10.1093/annonc/mdy424.038&rft_dat=%3Ccrossref%3E10_1093_annonc_mdy424_038%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |